Investment Analysts’ updated eps estimates for Wednesday, June 13th:

Dougherty & Co began coverage on shares of AstroNova (NASDAQ:ALOT). Dougherty & Co issued a buy rating on the stock.

Armstrong World Industries (NYSE:AWI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “For 2018, Armstrong World expects net sales to grow 5-7% aided by a modest upturn in volume and average unit value (AUV) improvement. The company's EPS guidance is at $3.60-$3.82, reflecting a 19-27% growth year over year. Results will be supported by price increases, strong repair and remodel activity along with the continuation of positive new building construction activity. Productivity improvements in plants and focus on restructuring activities will aid the bottom line. Also, continued sales leverage and capital investments at Tectum will fortify its Architectural Specialty business. Moreover, investment in new products will drive Armstrong World’s growth. Over the past year, the stock has outperformed the industry. However, startup challenges will remain headwind for the expected double-digit EBITDA growth in 2018. Also, geopolitical uncertainty in the EMEA region remains a headwind.”

American States Water (NYSE:AWR) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Over the last one year, shares of American States Water have outperformed its industry’s rally. The company’s strength lies in its extensive water rights and strong credit ratings. The company makes systematic investments to strengthen the existing infrastructure and pay regular dividend, owing to its strong cash flow generation capacity. However, American States Water’s main drawback is its heavy dependence on a single state, California, for majority of its earnings. Plus, the company’s highly-regulated operations and risk of water contamination leading to an increase in operating costs could adversely impact its results. Aging water infrastructure is also a concern.”

CMS Energy (NYSE:CMS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “CMS Energy's regulated electric power operations in Michigan generate a relatively stable and growing earnings stream. Share price of the company has outperformed its industry rally in last twelve months. The company boasts a solid capital expenditure program to boost its infrastructural upgrades. It is currently focused on capacity maximization, reliability improvement, clean power generation and infrastructure upgrade. Moreover, CMS Energy boasts a solid capital expenditure program. It also focuses on strengthening electric utility operations. However, the company incurs significant costs related to the construction, operation, and closure of solid waste disposal facilities for coal ash. CMS Energy’s businesses are sensitive to commodity prices. An upward movement in fuel prices could increase the company’s cost of operations. Adverse decisions in regulatory cases may also negatively impact the company's earnings.”

ConocoPhillips (NYSE:COP) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $78.00 price target on the stock. According to Zacks, “ConocoPhillips is one of the largest exploration and production players in the world, based on proved reserves and production. We appreciate the company’s initiative to divest non-core assets as the explorer could divert the proceeds toward oil-rich Eagle Ford shale and Bakken shale. It is to be noted that during 2017, ConocoPhillips generated $16 billion from the asset sale program. The company expects compound annual growth rate (CAGR) of production from 2017 to 2020 of 22%. Five rigs that have been operating since 2017 will continue till 2020. Significant undrilled locations in the Eagle Ford shale will boost the company’s production. The company also enhanced its share buyback program. With this, ConocoPhillips will increase share repurchases during 2018 to $2 billion from the prior projection of $1.5 billion.”

Deutsche Post (FRA:DPW) was given a €34.00 ($39.53) target price by analysts at Nord/LB. The firm currently has a buy rating on the stock.

Exelon (NYSE:EXC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “In a year’s time, shares of Exelon Corporation have gained against the decline of its industry. Exelon is going to benefit from its $21 billion planned capital investment, focus on zero emission electricity generation and cost savings. The company continues with its hedging program to manage market risks and protect the value of its generation. Strong cash flow generation capacity will help it lower debt levels and increase value of its shareholders. However, Exelon is subject to the impact of commodity price volatility and price fluctuation in the wholesale markets. Stringent government regulation is also a cause of concern.”

Flex Pharma (NASDAQ:FLKS) was downgraded by analysts at LADENBURG THALM/SH SH from a buy rating to a neutral rating.

Momenta Pharmaceuticals (NASDAQ:MNTA) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “The FDA approval of Glatopa 40 mg should relieve Momenta after a bumpy ride. We are pleased with Momenta's efforts to bring biosimilars to the market. Momenta has collaborated with Mylan to develop, manufacture and commercialize six of its current biosimilar candidates. Both the companies will initiate a clinical trial of M710 — a proposed biosimilar of Eylea — in the first half of 2018. An Investigational New Drug application has been accepted by regulatory body. However, competition will limit market share gains in the glatiramer acetate market as Mylan won the FDA’s approval for a generic version of Copaxone 40 mg much earlier. Notably, this is the first generic of Copaxone that has been approved. In addition, Momenta suffered another setback when M834, a proposed biosimilar for Orencia, did not meet its primary pharmacokinetic end points in a phase I study. Shares have outperformed the industry in the last six months.”

Grupo Aeroportuario Centro Norte (NASDAQ:OMAB) was downgraded by analysts at UBS Group AG from an outperform rating to a market perform rating.

Grupo Aeroportr dl Pcfco SAB de CV (NYSE:PAC) was upgraded by analysts at UBS Group AG from a market perform rating to an outperform rating.

Silicon Motion Technology (NASDAQ:SIMO) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Silicon Motion provides microcontroller ICs for NAND flash storage devices and specialty RF ICs for mobile devices. Silicon Motion's shares have underperformed the industry in the past year. The company faces macroeconomic risks like political, economic and social instability and certain industry-specific regulations in geographies where the company operates. Intensifying competition in the USB flash drive controller market remains a major headwind. Going forward, dip in smartphones sales might prove to be a drag on the revenues. Nonetheless, the company expects the increase in the availability of 64 layer 3D NAND to bring down high NAND prices, which will eventually improve results. Acquisitions have supplemented the company's growth initiatives. Moreover, rebuilt inventory from company’s NAND flash partners bolstered eMMC controller sales also remains a positive.”

Scotts Miracle-Gro (NYSE:SMG) had its sell rating reaffirmed by analysts at Bank of America Corp. The firm currently has a $80.00 price target on the stock.

Sanofi (NYSE:SNY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. Particularly, we are optimistic on sales prospects of Dupixent, which could prove to be an important growth driver. The acquisitions of Ablynx and Bioverativ have strengthened Sanofi’s position in the rare blood disorders market. However, Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan.  Other headwinds include generic competition for many drugs and slower-than-expected uptake of new products like Praluent. Meanwhile, the performance of the Vaccines and Consumer Healthcare franchises has been soft lately. Shares have also underperformed the industry this year so far.  Nonetheless, Sanofi expects to return to growth in the second half of 2018.”

ReneSola (NYSE:SOL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ReneSola continues to benefit from a steady flow of contracts from both domestic and international customers. Coming to the domestic front, the company believes that China's rooftop solar market will provide a significant space for its expansion. Also, ReneSola remains focused on monetizing its project portfolio while looking for opportunities to expand its pipeline across key markets. However, ReneSola’s share price has underperformed its industry over the last three months. Also, the U.S. administration's imposition of 30% tariff on the import of solar panels and modules may have impacted ReneSola’s revenues adversely. Since, a significant portion of its revenues is denominated in foreign currencies, the company faces foreign currency exchange risk.”

Stewart Information Services (NYSE:STC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Stewart Information Services Corporation’s primary business is title insurance. Stewart issues policies through issuing locations on homes and other real property located in all 50 states, the District of Columbia and several foreign countries. Stewart also sells computer-related services and information, as well as mapping products and geographic information systems, to domestic and foreign governments and private entities. “

Strayer Education (NASDAQ:STRA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $123.00 price target on the stock. According to Zacks, “Shares of Strayer outperformed its industry so far this year. Also, earnings estimates for 2018 and 2019 moved up in the past 30 days. The company’s convenient, accessible and flexible educational programs are designed to meet the educational needs of working adults. Strayer University is lowering the cost of programs to enhance their affordability. Importantly, Strayer and Capella decided to merge in an all-stock deal of equal transactions, expected to close in the third quarter of 2018. Post completion, Strayer’s shareholders will own approximately 52% of the combined company. The merger is expected to ensure student success, positive employment outcomes and be accretive to Strayer’s earnings by 20-25% by 2019. However, tuition cuts and an unfavorable mix of students toward lower undergraduate tuition have resulted in declining revenue per student over the past few quarters.”

Stock Yards Bancorp (NASDAQ:SYBT) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Stock Yards Bancorp Inc. is a bank holding company. Its main subsidiary is Stock Yards Bank & Trust Company. The company provides banking, trust, investment management, private banking, and brokerage services. It operates in and around Louisville, Indianapolis, and Cincinnati. Stock Yards Bancorp Inc. is headquartered in Louisville, Kentucky. “

Tahoe Resources (NYSE:TAHO) (TSE:THO) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Tahoe Resources Inc. is engaged in the exploration and development of mineral properties in the United States for the mining of precious metals. It principally holds interests in the Escobal project located in southeastern Guatemala. Tahoe Resources Inc. is headquartered in Reno, Nevada. “

Tenet Healthcare (NYSE:THC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Shares of Tenet Healthcare have soared compared to the industry year to date. Strategic divestitures helped streamlining its core operations while accretive acquisitions are significantly strengthening its top line. Moreover, the company’s recently taken enterprise-wide cost-reduction program is likely to favor earnings going forward. Following a solid first quarter results, Tenet Healthcare has raised its 2018 guidance. The Zacks Consensus Estimate for 2018 and 2019 has been revised upward in the last 60 days. However, the company has a high level of uncollectible accounts leading to a mounting level of bad debt. Rising leverage ratio has induced a spike in interest expenses, weighing on the company’s margins. Tenet Healthcare has also been suffering lower revenues over the past many quarters. Also, the valuation of the company’s shares look stretched at the moment.”

Wright Medical Group (NASDAQ:WMGI) was upgraded by analysts at Guggenheim from a neutral rating to a buy rating.

Receive News & Ratings for AstroNova Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstroNova Inc and related companies with MarketBeat.com's FREE daily email newsletter.